This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy? [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
Its bet to become a leader in this field fell flat, the company largely fell into irrelevance, and its value decreased substantially. However, Inovio isn't dead in the water. The company might be mounting a comeback, with its shares up by 96% since the year started. Is Inovio Pharmaceuticals a good contrarian buy? Let's find out. What's going on with Inovio? Inovio Pharmaceuticals develops DNA-based medicines. It uses a proprietary platform to manufacture plasmids, or DNA molecules, that it can insert into patients' bodies (also using proprietary devices) and that are designed to help produce disease-specific antibodies. Inovio boasts eight programs in clinical trials, an impressive number for a biotech with a market cap of just $305 million. Still, most of its programs haven't made it to phase 3 studies. It discontinued the development of its coronavirus vaccine, INO-4800, in the U.S. after encountering a range of clinical and regulatory issues, not to mention the stiff compe
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is now covered by analysts at Stephens. They set an "overweight" rating and a $20.00 price target on the stock.MarketBeat
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is now covered by analysts at Stephens. They set an "overweight" rating and a $20.00 price target on the stock.MarketBeat
- Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- INOVIO Reports First Quarter 2024 Financial Results and Recent Business HighlightsPR Newswire
INO
Earnings
- 5/13/24 - Miss
INO
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- INO's page on the SEC website